Incyte Corporation (INCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Incyte Corporation (INCY) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($543.30 Million) by net assets ($5.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Incyte Corporation - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Incyte Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Incyte Corporation balance sheet liabilities for a breakdown of total debt and financial obligations.
Incyte Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incyte Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vantage Towers AG
HM:VTWR
|
N/A |
|
SNAM S.P.A. ADR 2
F:SNM0
|
N/A |
|
First Quantum Minerals Ltd
TO:FM
|
0.186x |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
0.034x |
|
EchoStar Corporation
NASDAQ:SATS
|
0.016x |
|
Telus Corp
TO:T
|
0.068x |
|
Vestas Wind Systems A/S
F:VWSA
|
0.241x |
|
Mirae Asset Daewoo Securities Co Ltd
KO:006800
|
-0.338x |
Annual Cash Flow Conversion Efficiency for Incyte Corporation (1993–2025)
The table below shows the annual cash flow conversion efficiency of Incyte Corporation from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see Incyte Corporation (INCY) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.15 Billion | $1.41 Billion | 0.274x | +181.93% |
| 2024-12-31 | $3.45 Billion | $335.34 Million | 0.097x | +1.67% |
| 2023-12-31 | $5.19 Billion | $496.49 Million | 0.096x | -56.90% |
| 2022-12-31 | $4.37 Billion | $969.94 Million | 0.222x | +11.64% |
| 2021-12-31 | $3.77 Billion | $749.49 Million | 0.199x | +516.64% |
| 2020-12-31 | $2.61 Billion | $-124.60 Million | -0.048x | -117.45% |
| 2019-12-31 | $2.60 Billion | $710.66 Million | 0.273x | +56.66% |
| 2018-12-31 | $1.93 Billion | $336.23 Million | 0.175x | +406.13% |
| 2017-12-31 | $1.63 Billion | $-92.99 Million | -0.057x | -107.85% |
| 2016-12-31 | $419.47 Million | $304.76 Million | 0.727x | +43.70% |
| 2015-12-31 | $171.16 Million | $86.54 Million | 0.506x | +192.50% |
| 2014-12-31 | $-48.04 Million | $26.26 Million | -0.547x | -1049.79% |
| 2013-12-31 | $-193.11 Million | $9.18 Million | -0.048x | -108.77% |
| 2012-12-31 | $-174.96 Million | $-94.83 Million | 0.542x | -23.89% |
| 2011-12-31 | $-227.08 Million | $-161.72 Million | 0.712x | +164.46% |
| 2010-12-31 | $-88.64 Million | $97.94 Million | -1.105x | -815.35% |
| 2009-12-31 | $-102.38 Million | $12.36 Million | -0.121x | -118.92% |
| 2008-12-31 | $-220.75 Million | $-140.86 Million | 0.638x | +9.81% |
| 2007-12-31 | $-159.52 Million | $-92.69 Million | 0.581x | -2.04% |
| 2006-12-31 | $-84.91 Million | $-50.37 Million | 0.593x | -88.71% |
| 2005-12-31 | $-19.40 Million | $-101.87 Million | 5.252x | +459.62% |
| 2004-12-31 | $78.52 Million | $-114.67 Million | -1.460x | -90.47% |
| 2003-12-31 | $154.33 Million | $-118.33 Million | -0.767x | -297.95% |
| 2002-12-31 | $302.41 Million | $-58.27 Million | -0.193x | -80.44% |
| 2001-12-31 | $440.20 Million | $-47.00 Million | -0.107x | -805.37% |
| 2000-12-31 | $622.69 Million | $-7.34 Million | -0.012x | +90.61% |
| 1999-12-31 | $170.30 Million | $-21.40 Million | -0.126x | -162.34% |
| 1998-12-31 | $179.60 Million | $36.20 Million | 0.202x | +50.58% |
| 1997-12-31 | $139.70 Million | $18.70 Million | 0.134x | -62.19% |
| 1996-12-31 | $45.20 Million | $16.00 Million | 0.354x | +284.07% |
| 1995-12-31 | $46.80 Million | $-9.00 Million | -0.192x | +26.74% |
| 1994-12-31 | $24.00 Million | $-6.30 Million | -0.263x | +3.95% |
| 1993-12-31 | $16.10 Million | $-4.40 Million | -0.273x | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more